Causes of Visual Acuity Loss among Patients with AIDS and Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy

Ophthalmology

Volumn 113, Issue 8, 2006, Pages 1441-1445

  Thorne, Jennifer E ^a,b   Jabs, Douglas A ^a,b   Kempen, John H ^c   Holbrook, Janet T ^b   Nichols, Charles ^c   Meinert, Curtis L ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANAMNESIS; ARTICLE; BLINDNESS; CATARACT; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; LABORATORY TEST; LEGAL ASPECT; MAJOR CLINICAL STUDY; OPHTHALMOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINITIS; RISK ASSESSMENT; VISUAL ACUITY; VISUAL IMPAIRMENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CATARACT; CYTOMEGALOVIRUS RETINITIS; HUMANS; IMMUNE SYSTEM; MACULAR EDEMA, CYSTOID; MALE; RECOVERY OF FUNCTION; RETINAL DETACHMENT; VISION DISORDERS; VISUAL ACUITY;

EID: 33746292408     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2006.03.022     Document Type: Article

References (23)

1. Jabs D.A., Holbrook J.T., Van Natta M.L., et al. Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 112 (2005) 771-779
2. Jabs D.A. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc 93 (1995) 623-683
3. Gallant J.E., Moore R.D., Richman D.D., et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 166 (1992) 1223-1227
4. Pertel P., Hirschtick R., Phair J., et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr 5 (1992) 1069-1074
5. Hoover D.R., Peng Y., Saah A., et al. Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression. Arch Ophthalmol 114 (1996) 821-827
6. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Ophthalmology 101 (1994) 1250-1261
7. Holbrook J.T., Jabs D.A., Weinberg D.V., et al. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol 121 (2003) 99-107
8. Jabs D.A., and Bartlett J.G. AIDS and ophthalmology. a period of transition. Am J Ophthalmol 124 (1997) 227-233
9. Jabs D.A., Van Natta M.L., Thorne J.E., et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 1. Retinitis progression. Ophthalmology 111 (2004) 2224-2231
10. Kempen J.H., Jabs D.A., Dunn J.P., et al. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immune deficiency syndrome. Arch Ophthalmol 119 (2001) 33-40
11. Jabs D.A., Van Natta M.L., Thorne J.E., et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy. 2. Second eye involvement and retinal detachment. Ophthalmology 111 (2004) 2232-2239
12. Kempen J.H., Jabs D.A., Wilson L.A., et al. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol 121 (2003) 466-476
13. Thorne J.E., Jabs D.A., Kempen J.H., et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology 113 (2006) 1432-1440
14. Zegans M.E., Walton R.C., Holland G.N., et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 125 (1998) 292-300
15. Karavellas M.P., Lowder C.Y., Macdonald C., et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis. a new syndrome. Arch Ophthalmol 116 (1998) 169-175
16. Robinson M.R., Reed G., Csaky K.G., et al. Immune-recovery uveitis in patients with cytomegalovirus retinitis taking highly active antiretroviral therapy. Am J Ophthalmol 130 (2000) 49-56
17. Nguyen Q.D., Kempen J.H., Bolton S.G., et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 129 (2000) 634-639
18. Karavellas M.P., Plummer D.J., MacDonald J.C., et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 179 (1999) 697-700
19. Jabs D.A., Van Natta M.L., Kempen J.H., et al. Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Am J Ophthalmol 133 (2002) 48-61
20. AIDS Clinical Trials Group (ACTG). Studies of Ocular Complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. Control Clin Trials 13 (1992) 22-39
21. Holland G.N., Buhles Jr. W.C., Mastre B., et al. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. use of a standardized system for the assessment of disease outcome. Arch Ophthalmol 107 (1989) 1759-1766
22. Ferris III F.L., Kassof A., Bresnick G.H., and Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 94 (1982) 91-96
23. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481